Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046705 | 0.92 | CHEK1 (0.44) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046717 | 0.90 | CHEK1 (0.52) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046827 | 0.89 | CHEK1 (0.46) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046715 | 0.88 | CHEK1 (0.46) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046779 | 0.88 | CHEK1 (0.45) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046736 | 0.87 | CHEK1 (0.49) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046810 | 0.87 | CHEK1 (0.46) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046702 | 0.86 | CHEK1 (0.48) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046718 | 0.86 | CHEK1 (0.43) | CHEK1KCNH2LMNAMMP13AURKA | |
| SCHEMBL6046797 | 0.85 | AURKA (0.51) | CHEK1KCNH2LMNAMMP13AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060035920-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2005118583-A1 | 2, 5-DIHYDRO-PYRAZOLO`4, 3-C!QUINOLIN-4-ONES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035920-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885KCNH2 3052/4885LMNA 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.